TPMT genotype, phenotype and thiopurine metabolites (527)

This is a second pilot round of Equalis’s external quality assessment scheme for TPMT genotype, phenotype and thiopurine metabolites. This external quality assessment scheme is aimed for laboratories carrying out analysis of the investigations included in the scheme. Participating laboratories may choose to report result for one or more of the included examinations, in addition, an interpretation of the results can also be submitted.   

The test material is frozen human whole blood with accompanying information about the level of B—Hemoglobin, B—RBC och B—Hct. 

Test material: 1 /round for analysis of DNA—TPMT genotype and B—TPMT activity 
1 /round for analysis of B—6-MMPN and B—6-TGN. 

Frequency: 1/year 

Examinations 
DNA—TPMT:c.238G>C (NM_000367.5, NG_012137.3) 

DNA—TPMT:c.460G>A (NM_000367.5, NG_012137.3) 

DNA—TPMT:c.719A>G (NM_000367.5, NG_012137.3) 

DNA—TPMT genotype according to *-nomenclature 

B—TPMT activity (nmol/gHb*h) 

B—6-MMPN (pmol/8*10^8Erc)

B—6-TGN (pmol/8*10^8Erc)  

Last date of registration: 2024-04-02 

Distribution date: 2024-04-22 

Price pilot round: 175 EUR (shipping cost may be added outside of Sweden) 

Swedish laboratories register on our Swedish site. Laboratories from Denmark or Norway register through their national distributors, DEKS (Denmark) or Noklus (Norway). Laboratories from other countries can send an application to participate as international participants. 

If the outcome is good after completion of this pilot round, the EQA scheme will be recurring, and participation will then continue automatically. Before the EQA scheme becomes recurring, all registered participants will receive information about the future design of the scheme and what the yearly participation fee will be. If the participant chooses not to continue their participation in the scheme, this must be notified to Equalis via the format “Termination of participation” at https://www.equalis.se/en/for-participants/participant-administration/